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Supplementary Methods 
Antibodies and chemicals 
The following antibodies were used: SOX11 (Abcam, Cambridge, MA), HA (C29F4), 
HDAC1, HDAC2, Histone H3, STAT3 and pY705 STAT3 (Cell Signaling Technology, 
Danvers, MA), CCND1 (M20), GAPDH, and LAMIN A/C (Santa Cruz, Dallas, TX), and 
H3K9/14Ac (Diagenode Inc., Denville, NJ). The following chemicals were used: 
cyclohexamide (Sigma, St. Louis, MO), SAHA, C646, AZD1480 (Selleck Chemicals, 
Houston, TX), and JAK inhibitor I (MilliporeSigma, Burlington, MA). IL21 was from R&D 
Systems (R&D Systems, Inc., Minneapolis, MN). 
DNA transfection and viral transduction 
DNA transfection was performed by mixing DNA with JetPrime (PolyplusTransfection, 
New York, NY) and following the manufacturer’s instructions. For retroviral transduction, 
a retroviral vector and a mixture of helper plasmids for viral envelope and gag/pol were 
transfected into HEK293T cells using JetPrime. Retroviral supernatants were harvested 
48 hours after transfection and were used to transduce ecotropic receptor-expressing 
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target cells by centrifugation at 1200 xg for one hour in 8 µg/ml polybrene. For lentiviral 
transduction, a lentiviral vector and a mixture of helper plasmids for viral envelope VSV-
G (pMD2.G) and Gag/Pol/Rev/Tat (psPAX2) were transfected into HEK293T cells using 
JetPrime. Lentiviral supernatants were combined 48 and 72 h after transfection and 
concentrated by centrifugation (100,000 xg for 2 h). Lentiviral transduction of target cells 
was performed by centrifugation at 1200 xg for one hour in 8 µg/ml polybrene. 
Cell viability measurement  
Cell viability was assessed by flow cytometric analysis for propidium iodide (PI) negative 
population. In some experiments, shRNA knockdown vectors also co-express eGFP 
and the fractions of PI-, eGFP+ were analyzed by flow cytometry over time and 
compared with the early time fractions. A reduction in the GFP+ fractions over time 
indicates reduced cell viability. 
Immunoprecipitation analyses 
Cells were lysed at 4X107 cells/ml in IP buffer from Pierce Biotechnology (25 mM 
Tris•HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol), in presence of 
1mM PMSF, 10 mM glycerophosphate, 1x concentration of Protease and Halt 
Phosphatase cocktail inhibitors for 30 min on ice. Lysates were cleared by centrifuging 
for 15 minutes at 14,000 xg at 4°C. Five micrograms of IgG1 isotype control was mixed 
with 50 ml of 1:1 slurry of PBS and protein A agarose beads and the mixture was added 
to 1 ml of lysate followed by one-hour incubation on a rotating mixer at 4°C. Lysates 
were cleared again by centrifugation for one minute at 2400 xg at 4°C. Supernatants 
were quantified for protein concentrations using the BCA protein assay. Approximately, 
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1.5 mg of lysate from each sample was incubated with 40 ml of 1:1 slurry of PBS and 
HA antibody (IgG1)-conjugated agarose beads (Sigma, St. Louis, MO) overnight on a 
rotating mixer at 4°C. Agarose beads were washed 4 times in 1ml of PBS containing 
0.5% NP40 for 10 min each and pelleted by centrifugation at 2400 xg for 5 min. After 
discarding the supernatant, washed agarose beads were suspended in 100 µl of 1x 
sample buffer containing 5 µl of beta-mercaptoethanol and heat denatured for 5 min at 
95°C. Samples were separated on 10% polyacrylamide gels and transferred to 
nitrocellulose membranes for western blot analysis. 
Chromatin immunoprecipitation 
Chromatin immunoprecipitation was performed using the ChIP Assay Kit (Millipore, 
Temecula, CA) according to manufacturer’s instructions. Briefly, two million 
formaldehyde-fixed cells were lysed in 200 µl of SDS lysis buffer and diluted to 2 ml in 
ChIP dilution buffer in the presence of protease inhibitors. Lysates were sonicated for 9 
cycles of 30-second pulse at 30% power with 1 min gap on ice. Lysates were pre-
cleared in salmon sperm DNA and protein A agarose by centrifugation. Prior to addition 
of antibody, 10% of the lysate was used for input and the remaining lysate was divided 
into two equal parts, one for IgG control and other for H3K9 AC9/14 or HDAC1 antibody. 
DNA was extracted by phenol-chloroform method and assayed by SYBR® Green-based 
RT-PCR. Phosphorylated STAT3 ChIP was performed with one million cells following 
the manufacturer’s protocol for EZ-magna ChIP A/G (Millipore, Temecula, CA). Primer 
sequences for ChIP-qPCR are shown in Supplementary Table S5. 
Cell fractionation  
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Five million cells were harvested and washed twice in PBS. The cell pellet was 
suspended in 300 µl of nuclear isolation buffer (NIB, 15 mM Tris-HCl pH 7.6, 60 mM 
KCl, 15 mM NaCl, 5 mM MgCl2, 1 mM CaCl2, 5.5% sucrose, 1mM DTT, 1x protease 
inhibitor and 1x phosphatase inhibitor cocktails). To these suspended cells, 300 µl of 
NIB buffer containing 0.6% of NP40 was added and incubated on ice for 5 min followed 
by centrifugation at 2000 r.p.m. for 5 min at 4°C and transferred to a new tube, followed 
by denaturation in the presence of 2-mercaptoethanol and 200 µl of 4x sample buffer at 
95°C. The pellet was washed twice in NIB buffer and re-suspended in 300 µl of nuclear 
extraction buffer (NEB, 25 mM Tris-HCl pH 8.0, 250 mM NaCl, 1mM EDTA, 10% 
glycerol, 0.5% NP-40, 1x protease inhibitor and 1x phosphatase inhibitor cocktails). 
DNA amount in the lysate was quantified and DNAse I was added to a ratio of 1U of 
enzyme to 4 µg of DNA for 1 h on ice. The reaction was stopped by adding EDTA and 
centrifuged at 13,000 r.p.m. for 30 min at 4°C. Supernatant was collected, denatured in 
the presence of 100 µl of 4x sample buffer and used as nuclear soluble fraction. The 
pellet was washed again in NEB buffer, sonicated and denatured in 200 µl of 1x sample 
buffer and used as nuclear insoluble fraction. 
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Supplementary Figures 
 
 
 
Supplementary Figure S1. CCND1 upregulates SOX11 expression. A. Immunoblot 
analysis of GRANTA-519 cells stably transduced with empty vector (EV) or WT CCND1-
HA constructs. Cell lysates (30 µg per lane) were separated by SDS-PAGE gel and 
immunoblotted with indicated antibodies. * non-specific band. B. Quantitative PCR 
(qPCR) analysis of SOX11 mRNA expression. Cell lines generated as described in (A) 
and mRNAs were harvested for SOX11 qPCR. Shown are the means of mRNA 
expression levels after normalization to GAPDH signals from four independent 
amplification experiments. Error bars, SD. **** P<0.0001 by a 2-sided Student t-test. 
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Supplementary Figure S2. Validation of SOX11 antibody specificity. A. UPN-1 cells 
were stably transduced with control or SOX11 shRNA and cell lysates were 
immunoblotted with indicated antibodies 2 days after transduction. B. GRANTA-519 
cells were stably transduced with empty vector (EV) or SOX11-expressing vector and 
cell lysates were immunoblotted with indicated antibodies. The reduction or increase in 
the immunoblot signals after SOX11 gene-specific knockdown (A) or overexpression 
(B), respectively, indicates the specificity of the SOX11 antibody. 
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Supplementary Figure S3. HDAC1 depletion upregulates SOX11 expression. A. 
qPCR analysis of HDAC1 and SOX11 mRNA expression in Z-138 cells transduced with 
control or HDAC1 shRNA. Shown are the means of mRNA expression levels after 
normalization to GAPDH signals from four independent amplification experiments. B. 
qPCR analysis of HDAC1 and SOX11 mRNA expression in GRANTA-519 cells stably 
transduced with control or HDAC1 shRNA. Shown are the means of mRNA expression 
levels after normalization to GAPDH signals from four independent amplification 
experiments. Error bars, SD. ** P<0.01, **** P<0.0001 by a 2-sided Student t-test. C. 
GRANTA-519 cells were generated as described in (B) and protein expression was 
analyzed by immunoblot analysis with indicated antibodies 3 days after transduction. 
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Supplementary Figure S4. Sequestration of HDAC1 from chromatin in CCND1 
overexpressing cells. Cytosolic, soluble and insoluble nuclear extracts were prepared 
as described in Materials and Methods from GRANTA-519 cells that stably expressed 
empty vector or WT CCND1-HA. The extracts were immunoblotted with indicated 
antibodies. LAMIN A and histone H3 were used to confirm nuclear fractions. Cyto, 
cytoplasmic; Nu, soluble nuclear fraction; Insol, insoluble nuclear fraction. Numbers 
below immunoblots are relative densitometric values of corresponding bands after 
normalization to LAMIN A signals.   
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Supplementary Figure S5. Correlation of SOX11 and CCND1 mRNA levels. 
Linear regression analysis of SOX11 and CCND1 mRNA levels from SOX11 positive 
cases (see Supplementary Table S6 for expression data in A and Supplementary 
Table S7 for expression data in B) using GraphPad Software. 
 
 
 
 
 
 
 
 
 
Supplementary Figure S6. Effect of STAT3 inhibition on SOX11 expression. A. 
JVM-2 cells were treated with indicated doses of the JAK1/2 inhibitor AZD1480 for 16 h 
and immunoblotted with indicated antibodies. B. GRANTA-519 cells were treated with 
indicated doses of the JAK inhibitor I (MilliporeSigma, Burlington, MA, USA), an inhibitor 
of STAT3, for 16 h and immunoblotted with indicated antibodies. 
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Supplementary Figure S7. Effect of increased STAT3 activity on SOX11 
expression. Z-138 cells were transduced with EV or constitutive active STAT3 (STAT3-
CA) and cell lysates were immunoblotted with indicated antibodies. 
 
 
 
 
Supplementary Figure S8. Little effect of IL21 on cell viability in some MCL cell 
lines. Indicated MCL cell lines were treated with 50 or 100 ng/ml of IL21 and viable cells 
(PI-negative) were assessed by flow cytometry at indicated times. Shown are the means 
of PI-negative fractions compared to untreated (UT) samples from at least two 
independent experiments. 
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Supplementary Figure S9. Effect of SOX11 knockdown on MCL cell viability. 
GRANTA (A) and MAVER-1 (B) cells were transduced with control or SOX11 shRNA 
lentiviral vector that coexpresses GFP. Shown are the means of GFP+ fractions 
compared to Day 2 from two independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S10. EP300 inhibition reduces SOX11 expression. 
Immunoblot analysis of indicated cells treated with 10 µM of C646 in serum-free 
medium for indicated times before cell lysates were prepared and separated by SDS-
PAGE gel, followed by immunoblotting with indicated antibodies. 
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Supplementary Tables 
 
 
Supplementary Table S1. Results of cell line authentication by short tandem 
repeat DNA profiling. 
 
 
 
 
 
 
Supplementary Table S2. MCL patient-derived xenografts. 
 
 
 
 
 
 
 
Supplementary Table S3. List of shRNA sequences. 
 
Short	tandem	repeat	proﬁle	
Locus	 JEKO-1	(a)	 Z-138	(a)	 GRANT-519	(b)	 UPN-1	(c)	
TH01	 7	 6	 7,	8	 8,	9.3	
D5S818	 10,	13	 11,	13	 9,	13	 12,	13	
D13S317	 8,	9	 9,	12	 9,	11	 13	
D7S820	 10,	11	 8	 10,	14	 11,	13	
D16S539	 12	 11	 12,	12	 13	
CSF1PO		 9,	12	 10,	11	 10,	10	 12	
Amelogenin		 X	 X,	Y	 X,	X	 X	
vWA	 14	 15,	18	 17,	17	 16,	18	
TPOX	 8	 8	 8,	8	 8,	9	
(a)	Proﬁle	matches	ATCC	Reference	Database	proﬁle	
(b)	Proﬁle	matches	DSMZ	Reference	Database	proﬁle	
(c)	Proﬁle	not	present	in	ATCC	and	DSMZ	Databases	
Case Name Age Gender Disease Stage Cytogenetics/Karyotype Exome-seq
98848 MCL PDX 4 81 M Relapse IGH-CCND1 by FISH NOTCH1P2514fs* KRASS136R
44685 MCL PDX 5 63 M Relapse t(11;14)(q13;q32) IGH-CCND1 ATMV1671fs* WHSC1E1009K CREBBPQ2257H
91438 MCL PDX 7 75 M Progressive IGH-CCND1 by FISH TET2N1103fs*
96069 MCL PDX 9 72 F Refractory t(11;14)(q13;q32) IGH-CCND1 BIRC3L548fs*
Gene Name in manuscript RNAi sequences Used in figures
CCND1 shCCND1 GCCGAGAAGCTGTGCATCTAC 1C, D
SOX11 shSOX11 CGCCAGCCAGAGCCCAGAGAA 1E, S2A
HDAC1 shHDAC1 GAGGAAAGTCTGTTACTACTA 3C; S3A-C
HDAC2 shHDAC2 CAGTCTCACCAATTTCAGAAA 3D
STAT3 shSTAT3 GCTGACCAACAATCCCAAGAA 5H, I
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Supplementary Table S4. Validation of SOX11 mRNA quantitative PCR assays. 
 
RT, reverse transcriptase; Ct, cycle threshold. Ct values are means of four independent amplication 
experiments ± S.D. 
 
 
 
 
 
 
Supplementary Table S5. List of PCR primers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ct	values	
RT+	cDNA	 RT-	mock	
SOX11	primer	1	 23.8	±	0.05	 39.0	±	0.59	
SOX11	primer	2	 25.2	±	0.24	 36.4	±	0.81	
GAPDH	primer	 23.2	±	0.13	 38.6	±	0.38	
Name	 Sequence	(5'-3')	 Assay	 References	
GAPDH	primer	F	 AAGGGCTCATGACCACAGTC	 RT-PCR		 		
GAPDH	primer	R	 GGATGACCTTGCCCACAG	 RT-PCR		 		
		 		 		 		
SOX11	primer	1-F	 ACTCCAATGTCTCTTTTGC	 RT-PCR		 Hamborg	2012	
SOX11	primer	1-R	 GAACGGACTTTTTTTTTTTTTTTTTGAAGAT	 RT-PCR		 Hamborg	2012	
		 		 		 		
SOX11	primer	2-F	 CATGTAGACTAATGCAGCCATTGG	 RT-PCR,	ChIP-qPCR	(amplicon	2)	 Vegliante	2011	
SOX11	primer	2-R	 CACGGAGCACGTGTCAATTG		 RT-PCR,	ChIP-qPCR	(amplicon	2)	 Vegliante	2011	
		 		 		 		
SOX11	primer	3-F	 GAGAGCTTGGAAGCGGAGA		 ChIP-qPCR	(amplicon	1)	 Vegliante	2011	
SOX11	primer	3-R	 AGTCTGGGTCGCTCTCGTC	 ChIP-qPCR	(amplicon	1)	 Vegliante	2011	
		 		 		 		
SOX11	primer	4-F	 GAGAGCTTGGAAGCGGAGA		 ChIP-qPCR	(amplicon	1)	 Vegliante	2011	
SOX11	primer	4-R	 CGTTCGATCTTGGACCATACC	 ChIP-qPCR	(amplicon	1)	 		
		 		 		 		
SOX11	primer	5-F	 GCAGGTGTTTGATAATGCCTC	 ChIP-qPCR	(amplicon	3)	 		
SOX11	primer	5-R	 GCCAGAGCAATACAGTGAGTAATC	 ChIP-qPCR	(amplicon	3)	 		
		 		 		 		
SOX11	primer	6-F	 TTGGCTTTAGAATGAGGG	 ChIP-qPCR	(amplicon	4)	 		
SOX11	primer	6-R	 TCACACTGAAGTTTTGATGGG	 ChIP-qPCR	(amplicon	4)	 		
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Supplementary Table S6. mRNA expression data from GSE16455 (ref. 34). 
 
 
 
 
 
 
 
Supplementary Table S7. mRNA expression data from GSE36000 (ref. 16). 
 
 
Cases	(SOX11	positive)
204915_s_at 204914_s_at 204913_s_at 208712_at 208711_s_at
Conventional.MCL.1 993.6 2779.6 2397 4288.1 3788 2056.733 4038.05
Conventional.MCL.10 546.7 2167.4 1475.6 504.8 617.9 1396.567 561.35
Conventional.MCL.11 683 2394.5 2237.8 633 694.7 1771.767 663.85
Conventional.MCL.13 460.8 1297.6 1468.2 4027.8 4413.9 1075.533 4220.85
Conventional.MCL.14 184.2 344.8 163 1071.3 1088 230.6667 1079.65
Conventional.MCL.15 384 1062.5 1320 1496.1 1184 922.1667 1340.05
Conventional.MCL.2 1087.1 2530.4 3369.9 3833.6 1351.1 2329.133 2592.35
Conventional.MCL.3 483.6 739.6 932 1824.7 1224.7 718.4 1524.7
Conventional.MCL.4 465.5 1719.3 1263.6 749.2 532.2 1149.467 640.7
Conventional.MCL.5 502.9 1307.6 1317.2 1671.9 1403.9 1042.567 1537.9
Conventional.MCL.6 296.1 708.6 735 2416 1293 579.9 1854.5
Conventional.MCL.7 148.9 328.2 415.6 434.7 500 297.5667 467.35
Conventional.MCL.9 555 1742.2 1415 561.6 1988.6 1237.4 1275.1
Indolent.MCL.4 239.2 553.3 368.2 2118.8 1231.1 386.9 1674.95
Indolent.MCL.2 137.7 222.5 174.7 2200.5 1324 178.3 1762.25
Cases	(SOX11	negative)
204915_s_at 204914_s_at 204913_s_at 208712_at 208711_s_at
Conventional.MCL.8 24.7 11.9 21.5 2.1 4951.4 19.36667 2476.75
Conventional.MCL.12 4.8 1.4 32.5 1349.8 906.3 12.9 1128.05
Indolent.MCL.1 12.5 2.3 0.6 857.4 508.1 5.133333 682.75
Indolent.MCL.3 2.9 25.4 24.7 2203 1398.5 17.66667 1800.75
Indolent.MCL.5 7.5 74 29.9 2055.6 922.4 37.13333 1489
Indolent.MCL.6 4.9 10.3 3.5 1485.1 746.7 6.233333 1115.9
Indolent.MCL.7 3.1 19.7 4.3 96.5 4792.7 9.033333 2444.6
SOX11 CCND1 SOX11	
average
CCND1	
average
SOX11 CCND1 SOX11	
average
CCND1	
average
Cases	(SOX11	positive)
204915_s_at 204913_s_at 204914_s_at 208712_at 208711_at
MCL_IGHV_UNMUT	(R1394) 10.3621 10.0579 11.1429 11.8866 11.1948 10.5209667 11.5407
MCL_IGHV_UNMUT	(R1306) 8.90176 9.34356 9.88933 8.99182 9.06118 9.37821667 9.0265
MCL_IGHV_UNMUT	(R1332) 8.72074 8.6211 9.92335 10.1699 9.72807 9.08839667 9.948985
MCL_IGHV_UNMUT	(R1587) 9.5396 7.53551 9.92012 2.67941 12.3112 8.99841 7.495305
MCL_IGHV_UNMUT	(R1680) 7.40145 9.46408 9.93824 9.83827 10.7875 8.93459 10.312885
MCL_IGHV_UNMUT	(268-01-5TR) 8.29182 7.66145 9.18539 9.05927 8.48165 8.37955333 8.77046
MCL_IGHV_UNMUT	(043-01-4TR) 11.3831 8.93468 11.0159 10.9781 8.74049 10.44456 9.859295
MCL_IGHV_UNMUT	(R1338) 7.88213 8.53114 8.80149 10.4192 10.1986 8.40492 10.3089
MCL_IGHV_UNMUT	(R1388) 9.02642 8.16175 9.71772 10.1339 10.0619 8.96863 10.0979
MCL_IGHV_MUT	(R1400) 8.05998 9.09335 9.34785 9.95061 10.2426 8.83372667 10.096605
MCL_IGHV_MUT	(R1628) 9.68681 10.8834 10.5004 10.9729 10.3333 10.35687 10.6531
MCL_IGHV_MUT	(R1629) 8.32904 9.00908 8.72256 9.70786 9.86063 8.68689333 9.784245
MCL_IGHV_MUT	(R1938) 8.65126 7.52828 9.32923 9.47836 9.17358 8.50292333 9.32597
SOX11 CCND1 SOX11	
average
CCND1	
average
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Supplementary Figure S11. Immunoblot analysis shows effect of CCND1 
knockdown on HDAC1 and HDAC2 expression. UPN-1 cells were transduced with 
control or CCND1 shRNA and cell lysates at the indicated times were immunoblotted 
with indicated antibodies. 
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Supplementary Figure S12. CCND1 upregulates SOX11 expression in Z-138 
and JEKO-1 cells. A. Immunoblot analysis of indicated MCL cell lines stably 
transduced with empty vector (EV), WT or Y44D mutant CCND1-HA constructs. 
Cell lysates were separated by SDS-PAGE gel and immunoblotted with indicated 
antibodies. Arrow indicates a mobility shift of the CCND1-HA protein. Arrowhead 
indicates endogenous CCND1. Numbers below immunoblots are relative 
densitometric values of corresponding bands after normalization to GAPDH and 
respective control signals.   
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Supplementary Figure S13. Comparison of rabbit and mouse anti-HDAC 
antibodies. Lysates from MCL# 15 and 24 were immunoblotted with rabbit and mouse 
anti-HDAC1 antibodies. In membrane 1, the blot was imaged using a BioRad Imaging 
system and two different exposures were shown. In membrane 2, the blot was exposed 
to X-ray films at two different times to normalize the signal intensities from the two 
different antibodies. In both membranes, the single band specific for HDAC1 was 
detected by the mouse antibody and used as a positive control for the HDAC1-specific 
band. This HDAC1 specific band lines up with the upper band detected by the rabbit 
antibody. This result suggests that the bottom band detected by the rabbit antibody is 
non specific (n.s.). 
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